European Journal of Cancer
Volume 37, Issue 4 , Pages 512-519 , March 2001

Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine?

  • M Cervello

      Affiliations

    • Institute of Developmental Biology, C.N.R., Via Ugo La Malfa 153, 90146 Palermo, Italy
    • ,
  • M Notarbartolo

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • M Landino

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • A Cusimano

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Via del Vespro 129, 90127 Palermo, Italy
    • ,
  • L Virruso

      Affiliations

    • Institute of Developmental Biology, C.N.R., Via Ugo La Malfa 153, 90146 Palermo, Italy
    • ,
  • G Montalto

      Affiliations

    • Institute of Internal Medicine, University of Palermo, Via del Vespro 143, 90127 Palermo, Italy
    • ,
  • N D'Alessandro

      Affiliations

    • Dipartimento di Scienze Farmacologiche, Via del Vespro 129, 90127 Palermo, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-91-655-3258; fax: 39-91-655-3249

Received 7 August 2000 ,Revised 16 October 2000 ,Accepted 18 October 2000.

References 

  1. Kawano M, Hirano T, Matsuda T, et al.  Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas. Nature. 1988;332:83–85
  2. Miki S, Iwano M, Miki Y, Yamamoto M, et al.  Interleukin-6 (IL-6) functions as an autocrine growth factor in renal cell carcinoma. FEBS Lett. 1989;250:607–610
  3. Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res. 1990;50:7786–7788
  4. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signalling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to VP-16 and CDDP-mediated cytotoxicity. Cancer. 1999;85:134–144
  5. Onozaki K, Akiyama Y, Okano A, et al.  Synergistic regulatory effect of interleukin 6 and interleukin 1 on the growth and differentiation of human and mouse myeloid leukemic cell lines. Cancer Res. 1989;49:3602–3607
  6. Chen L, Shulman LM, Revel M. IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells. J. Biol. Regul. Homeost. Agents. 1991;5:125–136
  7. Takizawa H, Ohtoshi T, Ohta K, et al.  Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro (a possible role in tumor growth via an autocrine mechanism). Cancer Res. 1993;53:4175–4181
  8. Lu C, Kerbel RS. Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell. Biol. 1993;120:1281–1288
  9. Falkson G, MacIntyre JM, Moertel CG. Primary liver cancer. Cancer. 1994;54:977–980
  10. Huggett AC, Ford CP, Thorgeirsson SS. Effects of interleukin 6 on the growth of normal and transformed rat liver cells in culture. Growth Factors. 1989;2:83–89
  11. Cressmann DE, Greenbaum LE, DeAngelis RA, et al.  Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:1379–1383
  12. Maione D, Di Carlo E, Li W, et al.  Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998;17:5588–5597
  13. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles B. Controlled synthesis of HBs Ag in differentiated human liver carcinoma-derived cell line. Nature (Lond.). 1979;282:615–616
  14. Nakajima K, Matsuda T, Fujitani Y, et al.  Signal transduction through IL-6 receptor (involvement of multiple protein kinases, Stat factors, and a novel H7-sensitive pathway). In:  Mackiewicz A,  Koj A,  Sehgal PB editor. Interleukin Cytokines. New York: Annals of the New York Academy of Sciences; 1995;p. 55–70
  15. de La Coste A, Romagnolo B, Billuart P, et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA. 1998;95:8847–8851
  16. Carruba G, Cervello M, Miceli MD, et al.  Truncated form of β-catenin and reduced expression of wild type catenins feature HepG2 human liver cancer cells. Ann. N.Y. Acad. Sci. 1999;886:212–216
  17. Bullions LC, Levine AJ. The role of β-catenin in cell adhesion, signal transduction and cancer. Curr. Opin. Oncol. 1998;10:81–87
  18. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (Lond.). 1999;398:422–426
  19. Orford K, Orford CC, Byers SW. Exogenous expression of β-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J. Cell. Biol. 1999;46:855–867
  20. Miyoshi Y, Iwao K, Nagasawa Y, et al.  Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 1998;58:2524–2527
  21. Morin PJ, Sparks AB, Korinek V, et al.  Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science. 1997;275:1787–1790
  22. Iwao K, Nakamori S, Kameyama M, et al.  Activation of the β-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res. 1998;58:1021–1026
  23. Satoh S, Daigo Y, Furukawa Y, et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Gen. 2000;24:245–250
  24. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin- proteasome pathway. EMBO J. 1997;16:3797–3804
  25. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J. Biol. Chem. 1997;272:24735–24738
  26. Ben-Ze'ev A, Geiger B. Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr. Opin. Cell. Biol. 1998;10:629–639
  27. Gabay C, Porter B, Guenette D, Billir B, Arend WP. Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1 beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. Blood. 1999;93:1299–1307
  28. Darzynkiewick Z, Bruno S, Del Bino G, Gorczyca W, Holz MA, Lassota P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795–798
  29. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometry detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods. 1995;184:39–51
  30. Murakami M, Hibi M, . Nakagawa N, et al.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993;260:1808–1810
  31. Sonne O, Davidsen O, Moller BK, Munck Petersen C. Cellular targets and receptors for interleukin 6. In vivo and in vitro uptake of IL-6 in liver and hepatocytes. Eur. J. Clin. Invest. 1990;20:366–376
  32. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA. 1996;93:8455–8459
  33. Citarella F, Felici A, Brower M, et al.  Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood. 1997;90:1501–1507
  34. Brancolini C, Sgorbissa A, Schneider C. Proteolytic processing of the adherens junctions components β-catenin and γ-catenin during apoptosis. Cell. Death Differ. 1998;5:1042–1050
  35. Fukuda K. Apoptosis-associated cleavage of beta-catenin in human colon cancer and rat hepatoma cells. Int. J. Biochem. Cell. B. 1999;31:519–529
  36. Kanemaki T, Kitade H, Kaibori M, et al.  Interleukin 1β and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology. 1998;27:1296–1303
  37. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 1999;274:23013–23019
  38. Fukada T, Hibi M, Yamanaka Y, et al.  Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STA3 in anti-apoptosis. Immunity. 1996;5:449–460
  39. Tamm I, Kikuchi T, Cardinale I, Krueger JG. Cell-adhesion-disrupting action of interleukin 6 in human ductal breast carcinoma cells. Proc. Natl. Acad. Sci. USA. 1994;91:3329–3333
  40. Asgeirsson KS, Olafsdottir K, Jonasson JG, Ögmundsdottir HM. The effects of IL-6 on cell adhesion and E-cadherin expression in breast cancer. Cytokine. 1998;10:720–728

PII: S0959-8049(00)00421-4

European Journal of Cancer
Volume 37, Issue 4 , Pages 512-519 , March 2001

Article Tools

* Image Usage & Resolution